The purpose of this study is to evaluate the safety, tolerability and efficacy of VX-121 combination therapy in subjects with cystic fibrosis (CF).
Key Inclusion Criteria:
Part 1: Heterozygous for F508del and an MF mutation (F/MF)
Part 2: Homozygous for F508del (F/F)
FEV1 value ≥40% and ≤90% of the predicted mean for age, sex, and height
Key Exclusion Criteria:
History of clinically significant cirrhosis with or without portal hypertension
Lung infection with organisms associated with a more rapid decline in pulmonary status
History of solid organ or hematological transplantation
Other protocol-defined Inclusion/Exclusion criteria may apply
April 20, 2023
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
For more information and to contact the study team: